Home IVA
4.38
  Price0.69%   +0.03
(After Hours: 4.38 +0.00 +0.00%)
loading

Inventiva S A (IVA) Latest News

Dec-02-22 08:11AM Humana (HUM) Ups '23 Medicare Advantage Membership Growth ViewZacks Investment Research
Dec-01-22 11:05AM Why You Should Retain Centene (CNC) in Your Portfolio NowZacks Investment Research
Nov-29-22 07:52AM What You Need to Know From UnitedHealth's (UNH) Latest OutlookZacks Investment Research
Nov-28-22 04:00AM Inventiva obtient un nouveau brevet élargissant la protection de la propriété intellectuelle de son produit candidat phare lanifibranor aux États-UnisGlobeNewswire Inc.
10:26AM Cigna (CI) Rises 18.9% in 6 Months: More Growth in Store?Zacks Investment Research
Nov-22-22 09:28AM Why You Should Add UnitedHealth (UNH) to Your Portfolio NowZacks Investment Research
Nov-16-22 08:39AM Teladoc (TDOC) Achieves Momentous 50M Milestone in VisitsZacks Investment Research
Nov-10-22 11:35AM Select Medical (SEM) Shares Fall 9.6% Since Q3 Earnings MissZacks Investment Research
Nov-08-22 11:01AM Why Is Encompass Health (EHC) Up 7.5% Despite Q3 Earnings Miss?Zacks Investment Research
10:54AM Teladoc (TDOC) Up 1.6% Since Q3 Earnings Beat on Higher VisitsZacks Investment Research
Nov-01-22 03:31AM Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From YesterdayBenzinga
Oct-31-22 12:21PM Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day SessionBenzinga
07:58AM Take the Zacks Approach to Beat the Market: Caterpillar, Amgen, Inventiva in FocusZacks Investment Research
Oct-31-22 06:36AM Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving PremarketBenzinga
Oct-25-22 05:41AM 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga
Oct-21-22 04:00AM Inventiva annonce la présentation d’un abstract scientifique lors du The Liver Meeting™ 2022 organisé par l’AASLD GlobeNewswire Inc.
Oct-19-22 02:16AM Elevance Health (ELV) Beats on Q3 Earnings, Ups '22 EPS ViewZacks Investment Research
Oct-18-22 05:27AM Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From YesterdayBenzinga
Oct-17-22 12:23PM Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day SessionBenzinga
06:30AM Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving PremarketBenzinga
Oct-12-22 11:35AM HCA Healthcare (HCA) Eyes 3 Hospital Divestments for $150MZacks Investment Research
Oct-10-22 05:28AM Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From FridayBenzinga
Oct-07-22 12:27PM Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day SessionBenzinga
07:49AM Why Avenue Therapeutics Is Trading Lower By 59%; Here Are 31 Stocks Moving PremarketBenzinga
Sep-26-22 01:37AM Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This AnalystBenzinga
Sep-22-22 03:10AM Dow Turns Higher; Crude Oil Rises 0.7%Benzinga
12:26PM Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day SessionBenzinga
Sep-22-22 12:26PM Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike HigherBenzinga
02:30AM Inventiva reports its 2022 first-half financial results and provides a corporate updateGlobeNewswire Inc.
Sep-21-22 04:40AM Inventiva et Sino Biopharm signent un accord de licence et de collaboration pour développer et commercialiser lanifibranor en ChineGlobeNewswire Inc.
Sep-08-22 09:35AM Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 WeeksZacks Investment Research
Jun-07-22 04:00AM  Inventiva intègre le segment Tech Leaders d’EuronextGlobeNewswire Inc.
Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Cap:    |  Volume (24h):